| Literature DB >> 27856150 |
O Ristow1, S Otto2, C Geiß3, V Kehl4, M Berger5, M Troeltzsch2, S Koerdt6, B Hohlweg-Majert7, C Freudlsperger5, C Pautke3.
Abstract
Recent studies have indicated that bone shows auto-fluorescence under an appropriate fluorescence lamp. The aim of this preliminary study was to compare the success rates of the established tetracycline fluorescence-guided bone surgery with auto-fluorescence-guided bone surgery in the treatment of medication-related osteonecrosis of the jaw (MRONJ). Forty patients suffering from MRONJ were referred for surgical treatment and were divided randomly into two groups: auto-fluorescence (n=20) or tetracycline fluorescence (n=20) guided bone surgery. The primary endpoint was treatment success, defined as the absence of exposed bone at 8 weeks after surgery. Secondary outcomes assessed were mucosal integrity, signs of infection, pain, and loss of sensitivity; these were evaluated descriptively at 10 days, 8 weeks, 6 months, and 1 year after surgery. At 8 weeks postoperative, 18/20 patients (90%) in the auto-fluorescence group and 17/20 patients (85%) in the tetracycline fluorescence group showed mucosal integrity (P>0.05). At the last follow-up, 94% in the auto-fluorescence group and 89% in the tetracycline fluorescence group presented complete mucosal coverage with no exposed bone, infection, or pain (P>0.05). There was no significant difference between the two techniques for any of the secondary outcomes (P>0.05). The results of this preliminary study show that auto-fluorescence-guided bone surgery has comparable success rates to the established tetracycline fluorescence-guided bone surgery.Entities:
Keywords: BRONJ; DRONJ; MRONJ; ONJ; VELscope; auto-fluorescence; bisphosphonate; bone; bone fluorescence; necrosis of the jaw; osteonecrosis; tetracycline; therapy
Mesh:
Substances:
Year: 2016 PMID: 27856150 DOI: 10.1016/j.ijom.2016.10.008
Source DB: PubMed Journal: Int J Oral Maxillofac Surg ISSN: 0901-5027 Impact factor: 2.789